The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities ...

Harrison, M.D. Interestingly, an increased risk for HCC in the setting of diabetes was not seen in a recent single-center study of ... showing steatosis and liver cancer. [85] Further study ...

Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will ...

Hepatocellular carcinoma (HCC) is a primary liver cancer that often occurs in patients with non-viral chronic liver disease ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

MARTINSBURG, WV — WVU Medicine Berkeley Medical Center is now offering a new treatment for liver cancer, according to a ...

Given the success of Research Topic <a href=" in Chemotherapy-Resistant Hepatocellular Carcinoma and the rapidly evolving ...

Given the continued lesion growth, hepatocellular carcinoma was suspected ... Dr. Dudzinski: The patient was referred to the cancer center of this hospital. He felt well and reported no new ...

Reply to: Importance of Defining Recurrence in Hepatocellular Carcinoma ... Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong ...